Molecular biology of human melanoma development and progression

Molecular Carcinogenesis

Volumn 23, Issue 3, 1998, Pages 132-143

  Sauter, Edward R ^a   Herlyn, Meenhard ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Melanoma; Treatment; Tumor markers

Indexed keywords

GANGLIOSIDE; INTEGRIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN; NERVE CELL ADHESION MOLECULE; PLATELET DERIVED GROWTH FACTOR; PLEIOTROPHIN; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL ADHESION; CELL PROLIFERATION; CONFERENCE PAPER; EXTRACELLULAR MATRIX; HUMAN; KARYOTYPE; MELANOMA; NONHUMAN; ONCOGENE C MYC; ONCOGENE H RAS; ONCOGENE K RAS; PRIORITY JOURNAL; SKIN CARCINOGENESIS; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

DISEASE PROGRESSION; HUMANS; MELANOMA;

EID: 0031757020     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199811)23:3<132::AID-MC2>3.0.CO;2-1     Document Type: Conference Paper

References (152)

1. Rigel DS. Epidemiology and prognostic factors in malignant melanoma. Ann Plast Surg 28:7-8, 1992.
2. Crombie IK. Racial differences in melanoma incidence. Br J Cancer 40:185-193, 1979.
3. Greene MH, Fraumeni JF. The hereditary variant of malignant melanoma. In: Clark WH, Goldman L, Mastrangelo MJ (eds), Human Malignant Melanoma. Grune and Stratton, New York, 1979, pp. 139-166.
4. Gallagher RP, McLean DI, Yang CP, et al. Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic nevi in children. Similarities to melanoma: The Vancouver mole study. Arch Dermatol 126:770-776, 1990.
5. Cifone MA, Fidler IJ. Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci USA 78:6949-6952, 1981.
6. Fuchs J, Packer L. Ultraviolet irradiation and the skin antioxidant system. Photodermatol Photoimmunol Photomed 7:90-92, 1990.
7. Penn I. Ultraviolet light and skin cancer. Immunol Today 6:206-207, 1985.
8. Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int J Cancer 42:319-324, 1988.
9. Ellem KAO, Cullinan M, Baumann KC, Dunstan A. UVR induction of TGF-α: A possible autocrine mechanism for the epidermal melanocytic response and for promotion of epidermal carcinogenesis. Carcinogenesis 9:797-801, 1988.
10. Peacocke M, Yaar M, Mansur CP, Chao MV, Gilchrest BA. Induction of nerve growth factor receptors on cultured human melanocytes. Proc Natl Acad Sci USA 85:5282-5286, 1988.
11. van Elsas A, Zerp SF, van der Flier S, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149:883-893, 1996.
12. Ley RD, Applegate LA, Padilla RS, Stuart TD. Ultraviolet radiation-induced malignant melanoma in Monodelphis domestica. Photochem Photobiol 50:1-5, 1989.
13. Romerdahl CA, Stephens LC, Bucana C, Kripke ML. The role of ultraviolet radiation in the induction of melanocytic skin tumors in inbred mice. Cancer Communications 1:209-216, 1989.
14. Setlow RB, Woodhead AD, Grist E. Animal model for ultraviolet radiation-induced melanoma: Platyfish-swordtail hybrid. Proc Natl Acad Sci USA 86:8922-8926, 1989.
15. Parmiter AH, Nowell PC. The cytogenetics of human malignant melanoma and premalignant lesions. In: Nathanson L (ed), Malignant Melanoma: Biology, Diagnosis, and Therapy. Kluwer Academic Publishers, Boston, MA, 1988, pp. 47-61.
16. Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 320:1367-1372, 1989.
17. Trent JM, Stanbridge EJ, McBride HL, et al. Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. Science 247:568-571, 1989.
18. Kirnbauer R, Kock A, Neuner P, et al. Regulation of epidermal cell interleukin-6 production by UV light and corticosteroids. J Invest Dermatol 96:484-489, 1991.
19. Wittbrodt J, Adam D, Malitscheck B, et al. Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in Xiphophorus. Nature 341:415-421, 1989.
20. Fountain JW, Karayiorgou M, Graw SL, et al. Chromosome 9p involvement in melanoma. Abstract. Am J Hum Genet 49:45, 1991.
21. Parmiter AH, Balaban G, Clark WH Jr, Nowell PC. Possible involvement of the chromosome region 10q24-q26 in early stages of melanocytic neoplasia. Cancer Genetics and Oncogenetics 30:313-317, 1988.
22. Platz A, Ringborg U, Brahme EM, Lagerlof B. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res 4:169-177, 1994.
23. Chevenix-Trench G, Martin NG, Ellem KAO. Gene expression in melanoma cell lines and cultured melanocytes: Correlation between levels of c-src-1, c-myc and p53. Oncogene 5:1187-1193, 1990.
24. Iwamoto T, Takahashi M, Ito M, et al. Aberrant melanogenesis and melanocytic tumor development in transgenic mice that carry a metallothionein/ref fusion gene. EMBO J 10:3167-3175, 1991.
25. Florenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O. Levels of nm23 messenger RNA in metastatic malignant melanomas: Inverse correlation to disease progression. Cancer Res 52:6088-6091, 1992.
26. Leone A, Flatow U, King CR, et al. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 65:25-35, 1991.
27. Volkenandt M, Schlegel U, Nanus DM, Albino AP. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res 4:35-40, 1991.
28. Stretch JR, Gatter KC, Ralfkiaer E, Lane DP, Harris AL. Expression of mutant p53 in melanoma. Cancer Res 51:5976-5979, 1991.
29. Bishop JAN. Molecular pathology of melanoma. Cancer Metastasis Rev 16:141-154, 1997.
30. Lassam N, Bickford S. Loss of c-kit expression in cultured melanoma cells. Oncogene 7:51-56, 1992.
31. Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 74:255-259, 1997.
32. Reymond A, Brent R. p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 11:1173-1178, 1995.
33. INK4a binding domain of CDK4 in familial melanoma Nat Genet 12:97-99, 1996.
34. Maelandsmo GM, Florenes VA, Hovig E, et al. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 73:909-916, 1996.
35. Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475-5483, 1996.
36. Castellano M, Gabrielli BG, Hussussian CJ, Dracopoli NC, Hayward NK. Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. J Invest Dermatol 109:61-68, 1997.
37. Matsumura Y, Yamagishi N, Miyakoshi J, Imamura S, Takebe H. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. Cancer Lett 115:91-96, 1997.
38. Gruis NA, van der Velden PA, Sandkuijl LA, et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10:351-353, 1995.
39. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.
40. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23-26, 1994.
41. Gause PR, Lluria-Prevatt M, Keith WN, et al. Chromosomal and genetic alterations of 7,12-dimethylbenz[a]anthracene-induced melanoma from TP-ras transgenic mice. Mol Carcinogen 20:78-87, 1997.
42. Glendening J, Flores J, Walker G, Stone S, Albino A, Fountain J. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumour progression in a sporadic melanoma patient. Cancer Res 55:5531-5535, 1995.
43. Quelle D, Zindy F, Ashmun R, Sherr C. Alternative reading frames of the INKa tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000, 1995.
44. Clark WH Jr. Human cutaneous malignant melanoma as a model for cancer. Cancer Metastasis Rev 10:83-88, 1991.
45. Clark WH Jr, Elder DE, Guerry D IV, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 15:1147-1165, 1984.
46. Greene MH. Rashomon and the procrustean bed: A tale of dysplastic nevi. J Natl Cancer Inst 83:1720-1724, 1991.
47. Clark WH Jr. Tumor progression and the nature of cancer Br J Cancer 64:631-644, 1991.
48. Herlyn M. Molecular and Cellular Biology of Melanoma. R.G. Landes Company, Austin, TX, 1993, pp. 44-92.
49. Valyi-Nagy IT, Herlyn M. Regulation of growth and phenotype of normal human melanocytes in culture. In: Nathanson L (ed), Cancer Treatment and Research, vol 5: Melanoma. Kluwer Academic Publishers, Boston, 1991, pp. 85-101.
50. Herlyn M, Graeven U, Speicher D, et al. Characterization of tanascin secreted by melanoma cells. Cancer Res 51:4853-4858, 1991.
51. Mancianti ML, Gyorfi T, Shih I-M et al. Growth regulation of cultured human nevus cells. J Invest Dermatol 100:281S-287S, 1993.
52. Herlyn M. Molecular and Cellular Biology of Melanoma. R.G. Landes Company, Austin, TX, 1993, pp. 21-43.
53. Balaban G, Herlyn M, Elder DE, et al. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet 11:429-439, 1984.
54. Rodeck U, Herlyn M, Menssen HD, Furlanetto RW, Koprowski H. Metastatic but not primary melanoma cells grow in vitro independently of exogenous growth factors. Int J Cancer 40:687-690, 1987.
55. Jambrosic J, Mancianti ML, Ricciardi RP, Sela BA, Koprowski H, Herlyn M. Transformation of normal human melanocytes and non-malignant nevus cells by adenovirus 12-SUYO hybrid. Int J Cancer 44:1117-1123, 1989.
56. Juhasz I, Albelda SM, Elder DE, Murphy GF, Valyi-Nagy IT, Herlyn M. Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol 143:528-537, 1993.
57. Dotto GP, Moellman G, Ghosh S, Edwards M, Halban R. Transformation of murine melanocytes by basic fibroblastic growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment. J Cell Biol 109:3115-3128, 1989.
58. Herlyn M, Menrad A, Koprowski H. Structure, function, and clinical significance of human tumor antigens. J Natl Cancer Inst 82:1883-1889, 1990.
59. Klein CE, Steinmayer T, Kaufmann D, Weber L, Brocker EB. Identification of a melanoma progression antigen as integrin VLA-2. J Invest Dermatol 96:281-284, 1991.
60. Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: Association of the β3 subunit with tumor progression. Cancer Res 50:6757-6764, 1990.
61. 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 89:1557-1561, 1992.
62. Moellmann GE, Kuklinska E, Klaus SN. Observations on the positions of melanocytes with respect to the epidermal basement membrane. Abstract. J Invest Dermatol 87:392, 1986.
63. Beck K, Hunter I, Engel J. Structure and function of laminin: Anatomy of a multidomain glycoprotein. FASEB J 4:148-160, 1990.
64. Kanemoto T, Reich R, Royce L, et al. Identification of an amino acid sequence from the laminin A chain that stimulates metastasis and collagenase IV production. Proc Natl Acad Sci USA 87:2279-2283, 1990.
65. Johnson JP, Stade BG, Holzmann B, Schwable W, Riethmuller G. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci USA 86:641-646, 1989.
66. Cillo C, Cantile M, Mortarini R, Barba P, Parmiani G, Anichini A. Differential patterns of HOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis. Int J Cancer 66:692-697, 1996.
67. Altomonte M, Colizzi F, Esposito G, Maio M. Circulating intercellular adhesion molecule 1 as a marker of disease progression in cutaneous melanoma. Letter. N Engl J Med 327:959, 1992.
68. Altomonte M, Carbone A, Ferrone S, Maio M. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 53:3343-3348, 1993.
69. Holzmann B, Brocker EB, Lehmann JM, et al. Tumor progression in human malignant melanoma: Five stages defined by either antigenic phenotypes. Int J Cancer 39:466-471, 1987.
70. Bardin N, Frances V, Lesaule G, Horschowski N, George F, Sampol J. Identification of the S-endo 1 endothelial associated antigen. Biochem Biophys Res Commun 218:210-216, 1996.
71. Pandolfi F, Trentin L, Boyle LA, et al. Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes. Cancer 69:1165-1173, 1992.
72. Wolf JM, Frank R, Mujoo K, Spiro RC, Reisfeld RA, Rathjen FG. A human brain glycoprotein related to the mouse cell adhesion molecule L1. J Biol Chem 263:11943-11947, 1988.
73. Denton KJ, Stretch JR, Gatter KC, Harris AL. A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol 167:187-191, 1992.
74. Elder DE, Rodeck U, Thurin J, et al. Antigenic profile of tumor progression in human melanocytic nevi and melanomas. Cancer Res 49:5091-5096, 1989.
75. Iliopoulos D, Ernst C, Steplewski Z, et al. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst 81:440-444, 1989.
76. Hersey P, Schibeci SD, Townsend P, Burns C, Cheresh D. Potentiation of lymphocyte response by monoclonal antibodies to the ganglioside GD3. Cancer Res 46:6083-6090, 1986.
77. Livingston PO, Adluri S, Helling F, et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275-1280, 1994.
78. Albino AP, Houghton AN, Eisinger M, et al. Class II major histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV (Ki-MSV) retroviruses. J Exp Med 164:1710-1722, 1986.
79. Rodeck U, Melber K, Kath R, Herlyn M. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol 97:20-26, 1991.
80. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 8:3685-3691, 1989.
81. Halaban R, Kwon BS, Ghosh S, Delli-Bovi P, Baird A. Fibroblast growth factor as an autocrine growth factor in melanomas. Oncogene Research 3:177-186, 1988.
82. Goldfarb M. The fibroblast growth factor family. Cell Growth Differ 1:439-445, 1990.
83. Presta M, Maier JAM, Rusnati M, Ragnotti G. bFGF is released from endothelial ECM in a biologically active form. J Cell Physiol 140:68-74, 1989.
84. Buckley-Sturrock A, Woodward SC, Senior RM, Griffin GL, Klagsbrun M, Davidson JM. Differential stimulation of collagenase and chemotactic activity in fibroblasts derived from rat wound repair tissue and human skin by growth factors. J Cell Physiol 138:70-78, 1989.
85. Adelaide J, Mattei M-G, Marics I, et al. Chromosomal localization of the hst oncogene and its co-amplification with the int-2 oncogene in human melanoma. Oncogene 2:413-416, 1988.
86. Derynck R. Transforming growth factor alpha. Cell 54:593-595, 1988.
87. Kim MK, Warren TC, Kimball ES. Purification and characterization of a low molecular weight transforming growth factor from the urine of melanoma patients. J Biol Chem 260:9237-9243, 1985.
88. Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 47:702-712, 1987.
89. Singletary SE, Baker FL, Spitzer G, et al. Biologic effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res 47:403-406, 1987.
90. Valverius EM, Walker-Jones D, Bates SE, et al. Production of and responsiveness to transforming growth factor-β in normal and oncogene-transformed human mammary epithelial cells. Cancer Res 49:6269-6274, 1989.
91. Pittelkow MR, Shipley GD. Serum-free culture of normal human melanocytes: Growth kinetics, and growth factor requirements. J Cell Physiol 140:565-576, 1989.
92. Westermark B, Johnson A, Paulsson Y, et al. Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor. Proc Natl Acad Sci USA 83:7197-7200, 1987.
93. Forsberg K, Valyi-Nagy I, Heldin C-H, Herlyn M, Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis. Development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 90:393-397, 1992.
94. Wellstein A, Fang W, Khatri A, et al. A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J Biol Chem 267:2582-2587, 1992.
95. Richmond A, Balentien E, Thomas HG, et al. Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin. EMBO J 7:2025-2033, 1988.
96. Wolpe SD, Cerami A. Macrophage inflammatory proteins 1 and 2: Members of a novel superfamily of cytokines. FASEB J 3:2565-2573, 1989.
97. Strieter RM, Kasahara K, Allen RM, et al. Cytokine-induced neurophil-derived interleukin-8. Am J Pathol 141:397-407, 1992.
98. Di Giovine FS, Duff GW. Interleukin 1: The first interleukin. Immunol Today 11:13-20, 1990.
99. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 135:3962-3968, 1985.
100. Giavazzi R, Garofalo A, Banie MR, et al. Interleukin 1 induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res 50:4771-4774, 1990.
101. Lu C, Vickers MF, Kerbel RS. Interleukin 6: A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 89:9215-9219, 1992.
102. Stracke ML, Engel JD, Wilson LW, Rechler MM, Liotta LA, Schiffman E. The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J Biol Chem 264:21544-21549, 1989.
103. Furlong RA. The biology of hepatocyte growth factor/scatter factor. BioEssays 14:613-617, 1992.
104. Halaban R, Rubin JS, Funasaka Y, et al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 7:2195-2206, 1992.
105. Walker MJ. Role of hormones and growth factors in melanomas. Semin Oncol 15:512-523, 1988.
106. Ghanem GE, Comunale G, Libert A, Vercammen-Grandjean A, Lejeune FJ. Evidence for α-melanocyte-stimulating hormone (α-MSH) receptors on human melanoma cells. Int J Cancer 41:248-255, 1988.
107. Lerner AB, McGuire JS. Melanocyte stimulating hormone and adrenocorticotropic hormone: Their relationship to pigmentation. N Engl J Med 270:539-546, 1964.
108. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 257:1248-1251, 1992.
109. Claffey KP, Brown LF, del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 56:172-181, 1996.
110. Potgens AJG, Lubsen NH, van Altena MC, Schoenmakers JGG, Ruiter DJ, de Waal RMW. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 146: 197-209, 1995.
111. Gitay-Goren H, Halaban R, Neufield G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 190:702-709, 1993.
112. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 57:443-478, 1988.
113. Yamanishi DT, Graham M, Buckmeier JA, Meyskens FL Jr. The differential expression of protein kinase C genes in normal human neonatal melanocytes and metastatic melanomas. Carcinogenesis 12:105-109, 1991.
114. Weiss SW, Langloss JM, Enzinger FM. Value of S-100 protein of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab Invest 49:299-308, 1983.
115. Hickie RA, Graham MJ, Buckmeier JA, Meyskens FL Jr. Comparison of calmodulin gene expression in human neonatal melanocytes and metastatic melanoma cell lines. Dermatology 99:764-773, 1992.
116. Westerman MA, Stoopen GM, van Muijen GN, Kuzincki J, Ruiter DJ, Bloemers HP. Expression of calcyclin in human melanoma cell lines correlates with metastatic behavior in nude mice. Cancer Res 52:1291-1296, 1992.
117. Woodbury RG, Brown JP, Loop SM, Hellstrom KE, Hellstrom I. Analysis of normal neoplastic human tissues for the tumor-associated protein p97. Int J Cancer 27:145-149, 1981.
118. Brown JP, Hewick RM, Hellstrom I, Hellstrom KE, Doolittle RF, Dreyer WJ. Human melanoma-associated antigen p97 is structurally and functionally related to transferrin. Nature 296:171-173, 1982.
119. Herlyn M, Malkowicz SB. Regulatory pathways in tumor growth and invasion. Lab Invest 65:262-271, 1991.
120. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, et al. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 115:191-199, 1991.
121. Woessner JR Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145-2154, 1991.
122. 2-macroglobulin secretion. Cell Regulation 1:895-905, 1990.
123. Menrad A, Speicher D, Wacker J, Herlyn M. Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res 53:1450-1455, 1993.
124. Valyi-Nagy IT, Shih I-M, Greenstein D, Elder DE, Herlyn M. Spontaneous and induced differentiation of cultured human melanoma cells. Int J Cancer 54:159-165, 1993.
125. McEwan M, Parsons PG, Moss DJ. Monoclonal antibody against human tyrosinase and reactive with melanocytic and amelanotic melanoma cells. J Invest Dermatol 90:515-519, 1988.
126. Herlyn M, Koprowski H. Melanoma antigens: Immunological and biological characterization and clinical significance. Annu Rev Immunol 6:283-308, 1988.
127. Herlyn M, Thurin J, Balaban G, et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 45:5670-4676, 1985.
128. Garigues HJ, Lark MW, Lara S, Hellstrom I, Hellstrom KE, Wight TN. The melanoma proteoglycan: Restricted expression of microspikes, a specific microdomain of the cell surface. J Cell Biol 103:1699-1710, 1986.
129. De Vries JE, Keizer GD, te Velde AA, et al. Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. Int J Cancer 38:465-473, 1986.
130. Van den Eynde B, Peelers D, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689-698, 1995.
131. Rogner UC, Wilke K, Steck E, Korn B, Poustka A. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics 29:725-731, 1995.
132. Brasseur F, Rimoldi D, Lienard D, et al. Expression of MAGE genes in primary and metastastic cutaneous melanoma. Int J Cancer 63:375-380, 1995.
133. Valmori D, Lienard D, Waanders G, Rimoldi D, Cerottini J-C, Romero P. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res 57:735-741, 1997.
134. Stone C, Lynch E, Linden M, Kubus J, Zarbo R. Immunocytochemical evaluation of proliferating cell nuclear antigen Ki-67 (MIB-1) and p53 in predicting survival of primary and metastatic malignant melanomas. Applied Immunohistochemistry 41:25-33, 1996.
135. Morales-Ducret C, van de Rijn M, Smoller B. Bcl-2 expression in melanocytic nevi. Arch Dermatol 131:915-918, 1995.
136. Livingston P, Wong G, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994.
137. Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J. Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46:3183-3191, 1986.
138. Rosenberg S, Packard B, Aebersold P, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676-1681, 1988.
139. Newton BJ. Current immunotherapy for melanoma. Cancer Surv 26:321-333, 1996.
140. Hart I. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 23:154-158, 1996.
141. Mittelman A, Wang X, Matsumoto K, Ferrone S. Antiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 14:175-181, 1995.
142. Hersey P. Melanoma vaccines. Current status and future prospects. Drugs 47:373-382, 1994.
143. Morton D, Foshag L, Hoon D, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-483, 1992.
144. Jaeger E, Bernhard H, Romero P, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumour vaccines with melanoma-associated antigens. Int J Cancer 66:162-169, 1996.
145. Garbe C, Krasagakis K. Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 100:239S-243S, 1993.
146. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-484, 1989.
147. Reinigen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 225:1-14, 1997.
148. Morton DL, Wen DR, Cochran AJ. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy or "watch and wait." Surg Oncol Clin N Am 1:247-259, 1992.
149. Reinigen DS, Cruse CW, Berman C, et al. An orderly progression of melanoma nodal metastases. Ann Surg 220:759-767, 1994.
150. Heller R, Becker J, Wassalle J, et al. Detection of submicroscopic lymph node metastases in patienls with malignant melanoma. Arch Surg 126:1455-1460, 1991.
151. Reinigen DS, Albertini J, Berman C, et al. Accurate nodal staging of malignant melanoma. Journal of the Moffitt Cancer Center 2:405-414, 1995.
152. Dale P, Wang Y, Conrad A, et al. Multiple marker polymerase chain reaction assay for evaluating circulating melanoma cells. Abstract. Proceedings of the American Society of Clinical Oncology 14:413, 1995.